Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today that company founder, CEO and president, Kathleen Danenberg, will present at the 2011 Gastrointestinal Cancers Symposium in San Francisco, January 20-22.

Ms. Danenberg will discuss the use of predictive and prognostic markers in the treatment of esophageal-gastric cancers during the “Cancers of the Esophagus and Stomach: Translational Research” session, scheduled from 9:45 AM – 1:15 AM, on January 20.

“Based upon strong scientific and medical evidence, the use of predictive biomarkers is gaining acceptance in the treatment of gastrointestinal cancers,” said Kathleen Danenberg. “Already, certain molecular markers appear to viably predict therapeutic response, and others are being actively investigated. By working together, the cancer care community is helping to optimize treatment decisions for the benefit of patients.”

The ASCO-GI annual meeting draws approximately 2,500 participants from around the world to discuss important advances in research and emerging therapies for gastrointestinal cancers.

About Response Genetics, Inc.

Response Genetics, Inc. (“RGI”) (the “Company”) (Nasdaq: RGDX) is focused on the development and sale of molecular diagnostic tests for cancer. RGI’s technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. In addition to diagnostic testing services, RGI generates revenue from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company was founded in 1999 and its principal headquarters are located in Los Angeles, California. For more information, please visit www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of RGI related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions, such as the ability of the Company to continue to analyze cancer samples, the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, the usefulness of gene profiling as a predictor of response to chemotherapy in gastrointestinal cancers, i and other statements identified by words such as “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans” or similar expressions.

These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.